Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of March 31, 2025 • 4:51 PM ET

Date/Time Source News Release
01/13/2025 06:30 AM EST ACCESSWIRE NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
01/08/2025 06:30 AM EST ACCESSWIRE Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
12/23/2024 06:30 AM EST ACCESSWIRE NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
11/15/2024 06:30 AM EST ACCESSWIRE NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
10/22/2024 06:30 AM EDT ACCESSWIRE NanoViricides President Dr. Diwan to Present at the PODD Conference
10/15/2024 06:30 AM EDT ACCESSWIRE NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
10/08/2024 06:30 AM EDT ACCESSWIRE NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
09/30/2024 06:30 AM EDT ACCESSWIRE NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
09/26/2024 06:30 AM EDT ACCESSWIRE NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs
08/26/2024 07:30 AM EDT ACCESSWIRE MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
Page

Additional News

As of March 31, 2025 • 4:51 PM ET

Date/Time Source News Release
03/12/2025 04:15 PM EDT Investing News Network Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines
03/11/2025 10:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
03/11/2025 07:30 AM EDT ACCESS Newswire NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
03/04/2025 08:35 AM EST InvestorBrandNetwork InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
03/04/2025 06:30 AM EST ACCESS Newswire Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
02/19/2025 11:43 AM EST InvestorBrandNetwork BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
02/19/2025 06:36 AM EST SeekingAlpha NanoViricides GAAP EPS of -$0.14
02/19/2025 06:30 AM EST ACCESS Newswire NanoViricides, Inc. Has Filed its Quarterly Report
02/11/2025 08:30 AM EST InvestorBrandNetwork InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Claims NV-387 Ready to Combat Bird Flu
02/11/2025 06:30 AM EST ACCESS Newswire NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.